DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 16.16
(0.56%)
CNY 16.16
(0.56%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 10.66 Billion CNY | 79.89% |
| 2022 | 5.93 Billion CNY | 12.44% |
| 2021 | 5.27 Billion CNY | 277.01% |
| 2020 | 1.39 Billion CNY | 324.91% |
| 2019 | 329.28 Million CNY | -6.67% |
| 2018 | 352.82 Million CNY | -31.51% |
| 2017 | 515.17 Million CNY | 25.91% |
| 2016 | 409.17 Million CNY | 57.17% |
| 2015 | 260.33 Million CNY | -48.95% |
| 2014 | 510 Million CNY | 75.86% |
| 2013 | 290 Million CNY | 129.8% |
| 2012 | 126.19 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 9.31 Billion CNY | -49.01% |
| 2024 Q1 | 11.54 Billion CNY | 8.21% |
| 2024 Q2 | 12.02 Billion CNY | 4.17% |
| 2023 Q2 | 5.7 Billion CNY | -3.5% |
| 2023 Q3 | 5.59 Billion CNY | -1.91% |
| 2023 Q4 | 10.66 Billion CNY | 90.71% |
| 2023 FY | 10.66 Billion CNY | 79.89% |
| 2023 Q1 | 5.91 Billion CNY | -0.35% |
| 2022 Q4 | 5.93 Billion CNY | 5.48% |
| 2022 Q3 | 5.62 Billion CNY | 0.55% |
| 2022 Q1 | 5.45 Billion CNY | 3.45% |
| 2022 FY | 5.93 Billion CNY | 12.44% |
| 2022 Q2 | 5.59 Billion CNY | 2.47% |
| 2021 Q4 | 5.27 Billion CNY | 4.45% |
| 2021 FY | 5.27 Billion CNY | 277.01% |
| 2021 Q2 | 4.91 Billion CNY | 8.13% |
| 2021 Q1 | 4.54 Billion CNY | 224.61% |
| 2021 Q3 | 5.05 Billion CNY | 2.84% |
| 2020 Q1 | 199.03 Million CNY | -39.56% |
| 2020 Q2 | 177.84 Million CNY | -10.64% |
| 2020 Q4 | 1.39 Billion CNY | 686.73% |
| 2020 FY | 1.39 Billion CNY | 324.91% |
| 2020 Q3 | 177.84 Million CNY | 0.0% |
| 2019 Q1 | 350.14 Million CNY | -0.76% |
| 2019 FY | 329.28 Million CNY | -6.67% |
| 2019 Q2 | 1.21 Billion CNY | 246.32% |
| 2019 Q4 | 329.28 Million CNY | -68.09% |
| 2019 Q3 | 1.03 Billion CNY | -14.9% |
| 2018 Q1 | 465.47 Million CNY | -9.65% |
| 2018 Q2 | 538.78 Million CNY | 15.75% |
| 2018 Q3 | 601.19 Million CNY | 11.58% |
| 2018 Q4 | 352.82 Million CNY | -41.31% |
| 2018 FY | 352.82 Million CNY | -31.51% |
| 2017 Q4 | 515.17 Million CNY | 10.04% |
| 2017 Q2 | 534.42 Million CNY | 34.67% |
| 2017 Q3 | 468.17 Million CNY | -12.4% |
| 2017 Q1 | 396.83 Million CNY | -3.02% |
| 2017 FY | 515.17 Million CNY | 25.91% |
| 2016 FY | 409.17 Million CNY | 57.17% |
| 2016 Q4 | 409.17 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2015 FY | 260.33 Million CNY | -48.95% |
| 2015 Q4 | 260.33 Million CNY | 0.0% |
| 2015 Q1 | 331.55 Million CNY | 0.0% |
| 2015 Q2 | 331.55 Million CNY | 0.0% |
| 2014 FY | 510 Million CNY | 75.86% |
| 2013 FY | 290 Million CNY | 129.8% |
| 2012 FY | 126.19 Million CNY | 0.0% |